T2 Biosystems (TTOO) announces agreement for COVID-19 tests
T2 Biosystems a leader in the rapid detection of sepsis-causing pathogens, announced that it has entered into a worldwide licensing agreement to develop a novel COVID-19 test to be rapidly manufactured. Tests will undergo by healthcare professionals within the Hackensack Meridian Healthnetwork, under the U.S. Food and Drug Administration’s Emergency Use Authorization guidance, to test and treat patients suspected of having coronavirus. With this said, part of the agreement is that T2 Biosystems will adapt the COVID-19 test for run on it’s T2Dx® Instrument, the same instrument used for the FDA-cleared T2Bacteria® and T2Candida® Panels.
“This agreement combines our FDA-cleared T2Dx platform with our joint scientific expertise to benefit patients at risk for both primary coronavirus infections, as well as associated secondary infections that may lead to sepsis,” said John Sperzel, President and Chief Executive Officer of T2 Biosystems. “Data from prior flu pandemics indicated bacterial co-infection rates as high as 29%, and sepsis rates above 30% among patients admitted to hospital intensive care units. The ability to detect coronavirus and associated secondary bacterial or fungal infections that may lead to sepsis, without the need to wait days for a diagnostic result, allows clinicians to achieve targeted therapy faster, and can lead to reduced length of stay in the intensive care unit, freeing up beds for incoming patients.”
The need for new tests is growing every day as the virus spreads at an alarming rate and T2 Biosystems will be able to provide a comprehensive assessment of patients suspected of primary or secondary infections associated with coronavirus, when timely results.